Disclosed is the use of 5-(3-difluoromethyl-4-fluoro-phenyl)-3-(2-methyl-imidazol-1-yl-methyl)-pyridazine, represented by general formula (I), or pharmaceutically acceptable salts thereof, for the manufacture of a medicament formulated for administration to provide a total daily dose from about 2 to about 50 mg of the compound of formula (I) for the treatment, prevention or amelioration of cognitive impairment, a neurodegenerative disease, pain, depression, attention deficit hyperactivity disorder, or addiction.
METHODS FOR TREATING DISORDERS USING NMDA NR2B-SUBTYPE SELECTIVE ANTAGONIST